

Silvia Antolin Novoa

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2447174/silvia-antolin-novoa-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

582
citations

13
h-index

24
g-index

34
ext. papers

776
ext. citations

4
avg, IF

2.86
L-index

#	Paper	IF	Citations
29	Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 853-857	5.1	1
28	Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study. <i>Annals of Surgical Oncology</i> , 2021 , 28, 958-967	3.1	5
27	Trajectories of alcohol consumption during life and the risk of developing breast cancer. <i>British Journal of Cancer</i> , 2021 , 125, 1168-1176	8.7	0
26	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. <i>Scientific Reports</i> , 2020 , 10, 7741	4.9	4
25	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. <i>Nutrients</i> , 2020 , 12,	6.7	2
24	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. <i>European Journal of Cancer</i> , 2019 , 120, 54-64	7.5	13
23	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 115-125	4.4	7
22	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. <i>Scientific Reports</i> , 2019 , 9, 3904	4.9	12
21	Radiation-induced angiosarcoma of the breast in a Li-Fraumeni patient. <i>Cirugía Española</i> , 2019 , 97, 114-116.	7	3
20	A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothed or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. <i>Investigational New Drugs</i> , 2019 , 37, 98-108	4.3	22
19	NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 133	8.3	15
18	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 693-701	4.4	18
17	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. <i>Breast Cancer: Targets and Therapy</i> , 2019 , 11, 29-42	3.9	1
16	Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3134-3143	2.2	29
15	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2018 , 9, 26406-26416	3.3	76
14	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 2213-2221	10.1	109
13	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , 2017 , 144, 577-585.	4.9	27

12	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , 2017 , 8, 73144-73153	3.3	19
11	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017 , 22, 1301-1308	5.7	10
10	Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1017-1017	2.2	2
9	Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2016 , 116, 1914-1924.e6	3.9	15
8	Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. <i>BMC Cancer</i> , 2015 , 15, 297	4.8	60
7	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. <i>PLoS ONE</i> , 2015 , 10, e0126096	3.7	39
6	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 507-15	4.4	46
5	Evaluaci3n de un programa de reconstrucci3n mamaria inmediata mediante expansi3n-pr3tesis en mujeres con c3ncer de mama. <i>Revista De Senologia Y Patologia Mamaria</i> , 2014 , 27, 10-18	0.1	
4	Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. <i>Cancer</i> , 2012 , 118, 241-7	6.4	25
3	A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study. <i>Clinical and Translational Oncology</i> , 2011 , 13, 686-91	3.6	3
2	Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine. <i>Clinical and Translational Oncology</i> , 2010 , 12, 450-2	3.6	1
1	Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 1185-95	4.9	13